Advanced Medical Optics, Inc. Announces Final Results of Modified Dutch Auction Tender Offer for Its 9-1/4% Senior Subordinated Notes.

Business Editors

SANTA ANA, Calif.--(BUSINESS WIRE)--July 23, 2003

Advanced Medical Optics, Inc. (NYSE: AVO) ("AMO") today announced final results of its "Modified Dutch Auction" tender offer (the "Offer") for up to $115.0 million aggregate principal amount at maturity (the "Offer Amount") of its outstanding 9-1/4% Senior Subordinated Notes due 2010 (the "Notes"). The Offer commenced on June 18, 2003 and expired at 12:00 midnight on July 18, 2003 (the "Expiration Date").

Based on a final count by The Bank of New York, the depositary for the Offer, a total of $177,640,000 aggregate principal amount at maturity of Notes was properly tendered by holders of Notes as of the Expiration Date. In accordance with the terms of the Offer, including the pro-ration terms thereof, AMO has accepted for payment the full $115.0 million aggregate principal amount at maturity of Notes subject to the Offer as set forth below. The final purchase price was set at $1,150 per $1,000 aggregate principal amount at maturity of Notes, the maximum offer price in the Offer. AMO will pay the same purchase price for all Notes accepted for payment, resulting in an aggregate payment of $132,250,000, plus accrued and unpaid interest thereon to, but not including, the date of purchase. Due to the over-subscription, AMO has accepted and will purchase, in accordance with the terms of the Offer, the full Offer Amount as follows: (i) all $107,140,000 aggregate principal amount at maturity of Notes tendered below the purchase price and (ii) $7,860,000 aggregate principal amount at maturity of the $70,500,000 aggregate principal amount at maturity of Notes tendered at the purchase price, which reflects a pro-ration factor of 11.1489362%. Tenders made below the purchase price were not subject to pro-ration.

Payment for Notes properly tendered and accepted for purchase, and the return of all other Notes tendered but not accepted for purchase, will be made promptly by The Bank of New York, the depositary for the Offer.

Morgan Stanley & Co. Incorporated acted as exclusive dealer manager and Mellon Investor Services LLC acted as information agent in connection with the Offer.

About Advanced Medical Optics

Advanced Medical Optics, Inc. is a global leader in the development, manufacturing and marketing of ophthalmic surgical and eye care products. The Company focuses on developing a broad suite of innovative technologies and devices to address a wide range of eye disorders. Products in the ophthalmic surgical line include foldable intraocular lenses, phacoemulsification systems, viscoelastics and related products used in cataract surgery, and microkeratomes used in LASIK procedures for refractive error correction. AMO owns or has the rights to such well-known ophthalmic surgical product brands as PhacoFlex(R), Clariflex(R), Array(R) and Sensar(R) foldable intraocular lenses, the Sovereign(R) phacoemulsification system and the Amadeus(TM) microkeratome. Products in the eye care line include disinfecting solutions, daily cleaners, enzymatic cleaners and lens rewetting drops. Among the well-known eye care product brands the Company possesses are COMPLETE(R), COMPLETE(R) Blink-N-Clean(R), Consept(R)F, Consept(R) 1 Step, Oxysept(R) 1 Step, Ultracare(R), Ultrazyme(R), Total Care(R) and blink(TM). Amadeus(TM) is a licensed product of, and a trademark of, SIS, Ltd.

Advanced Medical Optics, Inc. is based in Santa Ana, California, and employs approximately 2,000 worldwide. The Company has operations in about 20 countries and markets products in approximately 60 countries. For more information, visit the Company's web site at www.amo-inc.com.

Forward-Looking Statements

This press release contains forward-looking statements about AMO, including those relating to the Offer. All forward-looking statements in this press release are based on estimates and assumptions and represent AMO's judgment only as of the date of this press release. Actual results may differ from current expectations based on a number of factors including but not limited to changing market conditions and matters generally affecting the domestic and global economy, such as changes in interest and currency exchange rates. Therefore, the reader is cautioned not to rely on these forward-looking statements. AMO disclaims any intent or obligation to update these forward-looking statements.

Additional information concerning these and other risk factors may be found in previous financial press releases issued by AMO. AMO's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Certain Factors and Trends Affecting AMO and its Businesses" in AMO's 2002 Form 10-K filed by AMO with the Securities and Exchange Commission on March 14, 2003 and in AMO's Form 10-Q for the quarter ended March 28, 2003 filed by AMO with the Securities and Exchange Commission on May 5, 2003, also include information concerning these and other risk factors. Copies of press releases and additional information about AMO are available on the World Wide Web at www.amo-inc.com, or you can contact the AMO Investor Relations Department by calling the number listed below.